Journals / Turkish Journal of Gastroenterology / 2012 / Cilt: 23 - Sayı: 5

Kronik hepatit C hastalarında fibrozis ve viral yanıtı öngörmede basit non-invaziv belirteçler

Simple non-invasive markers as a predictor of fibrosis and viral response in chronic hepatitis C patients

Pages
538–545
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Top Summary Introduction Materials And Methods Results Discussion References

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Chronic hepatitis C has a high prevalence and leads to development of cirrhosis and hepatocellular carcinoma.
📊
Key Findings & Data:Materials and Methods: We performed a retrospective case-control study with utilization of non-invasive liver fibrosis test, platelet count, aspartate aminotransferase/alanine aminotransferase ratio, age-platelet index and aspartate aminotransferase to platelet ratio index, as a predictor of non-sustained viral response in chronic hepatitis C naive patients between July 2008 and August 2010 in İzmir Atatürk Training and Research Hospital.
💡
Conclusion & Impact:Top Summary Introduction Materials And Methods Results Discussion References
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Background/aims: Chronic hepatitis C has a high prevalence and leads to development of cirrhosis and hepatocellular carcinoma. Liver fibrosis staging is one of the main factors that influence the decision to indicate therapy for chronic hepatitis C carriers. Several simple laboratory tests, scores and indices have been proposed for the non-invasive prediction of hepatic fibrosis in patients with chronic hepatitis C. The purpose of this study was to evaluate non-invasive liver fibrosis tests as a predictive factor of fibrosis and non-sustained viral response (relapse/non-responder) in chronic hepatitis C naive patients. Materials and Methods: We performed a retrospective case-control study with utilization of non-invasive liver fibrosis test, platelet count, aspartate aminotransferase/alanine aminotransferase ratio, age-platelet index and aspartate aminotransferase to platelet ratio index, as a predictor of non-sustained viral response in chronic hepatitis C naive patients between July 2008 and August 2010 in İzmir Atatürk Training and Research Hospital. Results: We observed non-invasive liver fibrosis test to be highly effective in predicting non-sustained viral response patients, especially with age-platelet index (Accuracy=73%, OR=6.93, 95% CI, 2.41-19.8). A strong relationship was shown with multivariate analysis between non-sustained viral response and some non-invasive liver fibrosis tests such as viral load (OR=4.51, 95% CI, 1.16 17.6, p=0.03) and age-platelet index (OR=11.8, 95% CI, 2.25-62.15, p=0.004). Conclusions: If non-invasive tests could be standardized according to age, gender, race, and body mass index and individualized according to the fibrosis, then a nearly full correlation of non-invasive liver fibrosis test with histologic results could be obtained, stage of fibrosis could be predicted initially, sustained viral response/non-sustained viral response could be estimated, and the need for a repeat biopsy could be eliminated. Top Summary Introduction Materials And Methods Results Discussion References

Özet

Amaç: Kronik hepatit Cnin prevalansı yüksek olup, sirozis ve hepatosellüler karsinom gelişmesine neden olur. Kronik hepatit C taşı yıcılarında tedavi kararını etkileyen esas faktörlerden biri karaciğer fibrozisinin derecesidir. Kronik hepatit C hastalarında hepatik fibrozisi non-invaziv olarak öngörmede, bir kaç basit laboratuvar test, skor ve indeks önerilmektedir. Bu çalışmanın amacı, kronik hepatit C hastalarında tedaviye cevapsızlığı (relaps/non-responder) ve fibrozisi öngörmede non-invaziv karaciğer fibrozis testlerini değerlendirmekti. Gereç ve Yöntem: zmir Atatürk Eğitim ve Araştırma Hastanesinde Temmuz 2008 ile Ağustos 2008 tarihleri arasında naiv kronik hepatit C hastalarında platelet sayısı, aspartat aminotransferaz/alanin aminotransferaz oranı, yaş platelet indeksi ve aspartat aminotransferaz/platelet oranı gibi, non-invaziv karaciğer fibrozis testleri kaydedilerek retrospektif vaka kontrol çalışması yapıldı. Bulgular: Non-invaziv karaciğer fibrozis testlerini tedaviye cevapsız hastaları öngörmede, özellikle yaş-platelet indeksi olmak üzere, oldukça etkin saptadık (Doğruluk=73%, OR=6.93, 95% CI, 2.41-19.8). Yapılan çoklu analizde tedaviye cevapsızlık ve viral yük, yaş-platelet indeksi gibi bazı non-invaziv karaciğer fibrozis testleri arasında güçlü bir ilişki saptadı k. Sonuç: Non-invaziv testler yaş, cinsiyet, ırk, vücut kitle indeksi ve fibrozise gore bireyselleştirilebilirse, histolojik sonuçlarla tama yakın korelasyon sağlanabilir, fibrozisin derecesi başlangıçta öngörülebilir, tedaviye cevap/cevapsızlık tahmin edilebilir ve tekrarlayan biyopsi ihtiyacı ortadan kalkabilir.

🔖

Cite This Article

ARABUL, M., ASLAN, F., ALPER, E., AKPINAR, Z., ÇELİK, M., KANDEMİR, A., VATANSEVER, S., ÜNSAL, B. (2012). Kronik hepatit C hastalarında fibrozis ve viral yanıtı öngörmede basit non-invaziv belirteçler. Turkish Journal of Gastroenterology, Cilt: 23 - Sayı: 5, 538–545. https://ajindex.com/articles/411111

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Dienstage JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: 152-60
  2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52
  3. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2009; 49: 1335-74
  4. Sánchez-Tapias JM, Diago M, Escartıín P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60
  5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82
  6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55
  7. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99: 1160-74
  8. Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with chronic hepatitis C virus-related chronic liver disease. Arc Intern Med 2003; 163: 218-24
  9. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26
  10. Poynard T, Bedossa P, METAVIR and CLINIVIR Cooperative Study Groups. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. J Viral Hepat 1997; 4: 199-208
  11. Kleiner DE. The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. Semin Liver Dis 2005; 25: 52-64
  12. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J. Hepatol 1995; 22: 6969
  13. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-89
  14. Asselah T, Biéche I, Paradis V, et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007; 27: 13-27
  15. Lamn SL, Tram T, Zein NN. AASLD 2007: The future of hepatitis C.